文章名稱引用次數(shù)

• Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration Between 2013 and 201619
• Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics17
• Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation16
• Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study16
• Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 201715
• Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the Albumin-Mediated Hepatic Uptake Mechanism on the Basis of the Facilitated-Dissociation Model14
• A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes13
• The Roles of Xenobiotic Receptors: Beyond Chemical Disposition13
• Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites13
• The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model13